Nahdi Medical Company

4164

SA15HG521213

Drug Retailers

End-of-day quote Saudi Arabian S.E. Other stock markets 03:30:00 07/05/2024 am IST			5-day change	1st Jan Change
137 ^SAR	+0.44%		-0.87%	0.00%

18/03	Nahdi Medical Company Reports Earnings Results for the Full Year Ended December 31, 2023	CI
18/03	Nahdi Medical Posts Higher FY23 Net Profit, Revenue	MT

Nahdi Medical Company Reports Earnings Results for the Second Quarter Ended June 30, 2023

August 03, 2023

Nahdi Medical Company reported earnings results for the second quarter ended June 30, 2023. For the second quarter, the company reported sales was SAR 2,231.49 million compared to SAR 2,239.47 million a year ago. Net income was SAR 264.95 million compared to SAR 268.51 million a year ago.

Latest news about Nahdi Medical Company

Nahdi Medical Company Reports Earnings Results for the Full Year Ended December 31, 2023	19/03	CI
Nahdi Medical Posts Higher FY23 Net Profit, Revenue	18/03	MT
Nahdi Medical Company Approves Cash Dividend Distribution for the Second Half of 2023	17/03	CI
Nahdi Medical Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
OptiBiotix says market still "volatile" but partner sales improving	01/11	AN
Saudi Arabia healthcare group Fakeeh Care weighs IPO, appoints HSBC - sources	27/23/27	RE
Nahdi Medical Company Reports Earnings Results for the Second Quarter Ended June 30, 2023	03/23/03	CI
Nahdi Medical Company Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Nahdi Medical Company Reports Earnings Results for the Full Year Ended December 31, 2022	20/23/20	CI
Nahdi Medical Company Reports Earnings Results for the Third Quarter Ended September 30, 2022	06/22/06	CI
Nahdi Medical Company Reports Earnings Results for the Third Quarter Ended September 30, 2022	06/22/06	CI
OptiBiotix Health gets approval to sell products in Saudi Arabia	24/22/24	AN
OptiBiotix Health Plc Announces Exclusive Distributor Nahdi Medical Co Has Received Approval from the Saudi Food and Drug Authority for GoFigure Shakes and Bars Containing Patented Weight Management Aid Slimbiome	24/22/24	CI
Nahdi Medical Company Announces the Establishment of a New Company, Owned by its Subsidiaries	29/22/29	CI
Certain Ordinary Shares of Nahdi Medical Company are subject to a Lock-Up Agreement Ending on 20-SEP-2022.	20/22/20	CI
Nahdi Medical Company(SASE:4164) added to S&P Global BMI Index	19/22/19	CI
Nahdi Medical Company(SASE:4164) added to S&P Pan Arab Composite	19/22/19	CI
Nahdi Medical Company Announces Distribution of Cash Dividend for First Half of 2022, Payable on August 25, 2022	09/22/09	CI
Nahdi Medical Company(SASE:4164) added to FTSE All-World Index	30/22/30	CI
Nahdi Medical Company has completed an IPO in the amount of SAR 5.109 billion.	20/22/20	CI
Nahdi Medical Company has filed an IPO.	29/21/29	CI
OptiBiotix Health plc Signs Exclusive Sales and Distribution Agreement with Nahdi Medical Co	15/21/15	CI

Chart Nahdi Medical Company

Duration

Period

More charts

Company Profile

Al Nahdi Medical Company SJSC is a Saudi Arabia-based retail pharmacy and healthcare company. The Company is engaged in the wholesale and retail trading of cosmetics, pharmaceutical products, special and healthy foods and medical equipment. The Company operates two operating segments: Front Shop and Pharma. The Company provides medicine, wellness, mom & baby, beauty and other wide-ranging FMCG products. The Company provides omni-health services through its polyclinics, express clinics, telemedicine, labs, and home healthcare. The Company operates approximately 1,150 stores in 144 cities and towns in the Kingdom of Saudi Arabia and the United Arab Emirates. The Companyâs subsidiaries include Al Nahdi Care, Sakhaa Golden Company, and Nahdi Investment Company.

Sector

Drug Retailers

Calendar

14/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Nahdi Medical Company

Trading Rating

Investor Rating

ESG Refinitiv

D-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

137 SAR

Average target price

155.4 SAR

Spread / Average Target

+13.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Drug Retailers

	1st Jan change	Capi.
NAHDI MEDICAL COMPANY	0.00%	4.73B
WALGREENS BOOTS ALLIANCE, INC.	-33.55%	14.89B
JD HEALTH INTERNATIONAL INC.	-26.73%	12.2B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-29.01%	6.54B
YIFENG PHARMACY CHAIN CO., LTD.	+13.49%	6.37B
MATSUKIYOCOCOKARA & CO.	-10.11%	6.03B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+59.80%	4.57B
CLICKS GROUP LIMITED	-8.64%	3.82B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-10.56%	3.51B
WELCIA HOLDINGS CO., LTD.	-6.87%	3.07B

Other Drug Retailers